Honorary Doctorate of the University of Fribourg conferred on Prof. Federica Sallusto

At its Dies academicus, the University of Fribourg has conferred the title Doctor honoris causa (Dr. h. c.) on Prof. Federica Sallusto in recognition of her outstanding scientific and professional achievements.

by Dominic Dähler
Prof. Federica Sallusto
Prof. Federica Sallusto (ETH Zürich / Giulia Marthaler)

The Dies academicus was held in the Aula Magna on 15 November 2022. The University of Fribourg has awarded Federica Sallusto, head of the Institute for Research in Biomedicine (IRB) and professor at the Università della Svizzera italiana (USI) and the Swiss Federal Institute of Technology Zurich (ETH Zürich), the title of Doctor honoris causa in Biomedical Sciences for her numerous, substantial and innovative contributions in the field of immunology.

Federica Sallusto obtained her PhD in Biological Sciences from the University of Rome and went on to do post-doctoral training at the Istituto Superiore di Sanità in Rome and at the Basel Institute for Immunology, of which she was a member from 1997 to 2000. She then moved to the Institute for Research in Biomedicine (IRB, affiliated to USI) in Bellinzona to head the Laboratory of Cellular Immunology. Here she also founded the Centre for Medical Immunology. Since 2017, she has been Full Professor of Medical Immunology at the Swiss Federal Institute of Technology Zurich (ETH Zurich, Institute of Microbiology) and the University of Lugano (USI), in the Faculty of Biomedical Sciences. Prof. Sallusto's professorship was established thanks to a generous donation from the Helmut Horten Foundation.

This title further confirms Federica Sallusto's scientific achievements, which have already been widely recognised by numerous awards and prestigious appointments including, most recently, as a member of the US National Academy of Sciences, one of the most significant and highest honours bestowed on academic researchers.

Link to the website of the Sallusto lab.

This contribution is based on the media release by the Institute for Research in Biomedicine (IRB), Bellinzona.

JavaScript has been disabled in your browser